NASDAQ:OTLK Oncobiologics Q4 2024 Earnings Report $2.68 +0.27 (+11.20%) Closing price 04:00 PM EasternExtended Trading$2.72 +0.03 (+1.31%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Oncobiologics EPS ResultsActual EPS-$0.77Consensus EPS -$0.83Beat/MissBeat by +$0.06One Year Ago EPSN/AOncobiologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncobiologics Announcement DetailsQuarterQ4 2024Date12/27/2024TimeBefore Market OpensConference Call DateFriday, December 27, 2024Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Oncobiologics Earnings HeadlinesOncobiologics FY2025 EPS Estimate Increased by HC WainwrightAugust 22 at 2:01 AM | americanbankingnews.comOncobiologics (NASDAQ:OTLK) Given "Neutral" Rating at Chardan CapitalAugust 17, 2025 | americanbankingnews.comCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just discovered a new way to do it with 10X less money.August 22 at 2:00 AM | Investors Alley (Ad)Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comOncobiologics (OTLK) to Release Quarterly Earnings on WednesdayAugust 12, 2025 | americanbankingnews.comOutlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseJuly 24, 2025 | globenewswire.comSee More Oncobiologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncobiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncobiologics and other key companies, straight to your email. Email Address About OncobiologicsOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics (NASDAQ:OTLK) and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.View Oncobiologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity Upcoming Earnings PDD (8/25/2025)BHP Group (8/25/2025)Bank Of Montreal (8/26/2025)Bank of Nova Scotia (8/26/2025)CrowdStrike (8/27/2025)NVIDIA (8/27/2025)Royal Bank Of Canada (8/27/2025)Snowflake (8/27/2025)Autodesk (8/28/2025)Marvell Technology (8/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access